BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Bristol-Myers Squibb Company 

345 Park Avenue

New York  New York  10154  U.S.A.
Phone: 212-546-4000 Fax: 212-546-4020


SEARCH JOBS




 Key Statistics


Email:
Ownership: Public

Web Site: Bristol-Myers Squibb
Employees:
Symbol: BMY
 





Collaborations

Gilead 

PanVera LLC 

Pharmagene Laboratories Limited 

Johnson & Johnson 

Amersham Biosciences 

Lexicon Genetics Incorporated 

Athersys  Athersys will provide Bristol-Myers Squibb with cell lines expressing validated drug targets produced using the RAGE-Validated Target technology. BMS plans to use its combinatorial chemistry capabilities to develop small molecule drug candidates against the validated targets.

Merck & Co.  Diabetes

Affinimark Technologies Inc. 

GlaxoSmithKline (North Carolina) 

Medarex, Inc. 

Gilead (Durham, NC) 

Phyton Biotech, Inc.  - Cancer

Gilead (Seattle, WA) 





 Company News
uniQure (QURE) Announces Closing Of Strategic Collaboration With Bristol-Myers Squibb (BMY) To Develop Gene Therapies For Cardiovascular Disease 5/26/2015 9:41:18 AM
Bristol-Myers Squibb (BMY) Receives Positive CHMP Opinion In The European Union For Nivolumab (Opdivo, Nivolumab BMS) For The Treatment Of Advanced Squamous Non-Small Cell Lung Cancer In Previously-Treated Patients 5/22/2015 9:30:50 AM
Bristol-Myers Squibb (BMY) Receives Amended FDA Breakthrough Therapy Designation For Investigational Daclatasvir-Based Hepatitis C Regimen 5/20/2015 11:20:57 AM
AbbVie (ABBV), Bristol-Myers Squibb (BMY) Drug Delays Blood Cancer Progression 5/14/2015 6:55:12 AM
Bristol-Myers Squibb (BMY) Announces The Pricing Terms Of Its Cash Tender Offer For Up To $500 Million Aggregate Principal Amount Of Its Outstanding Debt Securities 5/13/2015 1:23:34 PM
Bristol-Myers Squibb (BMY) To Present Data At 2015 ASCO Annual Meeting That Demonstrate The Promise Of Its Broad Immuno-Oncology Portfolio Across Solid Tumors And Blood Cancers Including Multiple Myeloma 5/13/2015 11:26:45 AM
Bristol-Myers Squibb (BMY) Announces The Early Results Of Its Cash Tender Offer For Up To $400 Million Aggregate Principal Amount Of Its Outstanding Debt Securities; Increases The Maximum Amount Of The Tender Offer 5/12/2015 8:07:24 AM
Bristol-Myers Squibb (BMY) Release: Long-Term, 7-Year Study Of Nulojix (Belatacept) Regimen Demonstrates Statistically Significant Relative Risk Reduction Of Death Or Graft Loss Over Cyclosporine Regimen In Kidney Transplant 5/6/2015 11:33:31 AM
Bristol-Myers Squibb (BMY) To Present At Bank of America (BAC) Merrill Lynch 2015 Health Care Conference 5/5/2015 10:57:01 AM
Bristol-Myers Squibb (BMY) Prices €1.15 Billion Of Senior Notes 4/30/2015 10:01:37 AM
12345678910...